• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glaukos drops $6m on Dose Medical’s IOP sensor system

April 13, 2017 By Sarah Faulkner

Glaukos logoGlaukos (NYSE:GKOS) said today that it acquired Dose Medical‘s intraocular pressure sensor system assets for $5.5 million in cash, plus $9.5 million contingent upon development, clinical and regulatory milestones.

The Dose Medical IOP sensor system includes a micro-invasive ocular implant that captures and stores a glaucoma patient’s short-interval IOP measurements. The system transmits data to the patient’s physician in the hopes of enhancing treatment.

The wireless system uses a rechargeable battery that is designed to allow the sensor to function for multiple years, Glaukos reported.

“This emerging IOP sensor system complements Glaukos’ fundamental strategy to transform glaucoma therapy with micro-scale device and drug-delivery platforms that can ultimately address a full range of disease state severity,” president & CEO Thomas Burns said in prepared remarks. “Although still in an early development phase, the system offers future promise as a 24/7 tool for measuring the effects of glaucoma medical and surgical interventions, monitoring patient therapeutic compliance and managing disease progression. Longer-term, we also see opportunities to build upon the sensor platform with additional diagnostic and IOP management innovations.”

Dose Medical was a wholly-owned subsidiary of Glaukos until 2010, when it was spun-out as a standalone entity.

Also today, Glaukos touted long-term data published in Clinical Opthalmology that showed that 2 of its iStent trabecular micro-bypass stents and 1 topical ocular hypotensive medication achieved a 38% reduction in mean medicated IOP 3 years following surgery in 37 phakic eyes.

The team plans on following patients through 5 years post-operative.

“The 3-year data demonstrate the long-term performance and safety of trabecular bypass stents and topical travoprost in subjects with OAG not controlled on two medications,” lead author Dr. David Chang said. “In addition, our results support the hypothetical synergy of using trabecular stents to increase outflow through the conventional aqueous fluid pathway while also using a prostaglandin analog such as topical travoprost to increase outflow through the uveoscleral, or unconventional, pathway.”

Glaukos’ iStent flagship device won FDA approval in 2012. It is inserted through the trabecular meshwork and into Schlemm’s canal through a small corneal incision made during cataract surgery. The device was designed to restore flow of aqueous fluid through the conventional pathway and reduce IOP.

The San Clemente, Calif.-based company is also seeking FDA approval for 2 versions of its next-gen iStent inject trabecular micro-bypass device – 1 for use with cataract surgery and the other for use in a standalone procedure.

GKOS shares were trading at $44.97 apiece in mid-morning activity, down -6.4%.

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: Dose Medical, Glaukos Corp.

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS